Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539823 | 0.86 | MAPK1 (0.63) | TSHRGAAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4888919 | 0.85 | HPGD (0.44) | TSHRGAAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL5189060 | 0.84 | TSHR (0.72) | TSHRGAAALDH1A1LMNAKDM4E | |
| SCHEMBL4087478 | 0.83 | TSHR (0.76) | TSHRALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL8619629 | 0.82 | MAPK1 (0.60) | TSHRGAAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3825267 | 0.82 | TDP1 (0.46) | TSHRGAASMN1; SMN2LMNAKDM4E | |
| SCHEMBL17096550 | 0.82 | CA1 (0.54) | TSHRGAAKDM4EMAPK1 | |
| SCHEMBL553679 | 0.79 | ALDH1A1 (0.57) | TSHRALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6538988 | 0.78 | NLRP3 (0.62) | GAAALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17444748 | 0.77 | PARP14 (0.63) | GAAALDH1A1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107674077-A | 8 [base of 3 amino piperidine 1] Xanthine compounds, its preparation method and purposes as pharmaceutical preparation | 勃林格殷格翰制药两合公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-105001222-B | 8 [base of 3 amino piperidine 1] Xanthine compounds, its preparation method and purposes as pharmaceutical preparation | 勃林格殷格翰制药两合公司 | 2017-11-07 | — | — | CN | disclosed |
| CN-102964347-B | 8-[3-amino-piperadine-1-base]-Xanthine compounds, its preparation method and the purposes as pharmaceutical preparation | BOEHRINGER INGELHEIM PHARMACEUTICAL CO., LTD. (DE) | 2015-11-18 | — | — | CN | disclosed |
| CN-105001222-A | New 8-(3-amino-piperidin-1-yl)-xanthine derivatives, preparing method and uses thereof as a pharmaceutic preparation | BOEHRINGER INGELHEIM PHARMA | 2015-10-28 | — | — | CN | disclosed |
| US-8445516-B2 | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20090187025-A1 | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1708705-B1 | USE OF PIPERIDINE DERIVATIVES FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMA CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1708705-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005072734-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | WO | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| EP-0102325-A1 | Monoazo dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1984-03-07 | — | — | EP | disclosed |
| EP-0101408-A1 | Monoazo dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187025-A1 | Pharmaceutical composition for promoting angiogenesis | FLT1, FLT4, KDR | TSHR 4330/4885GAA 2078/4885ALDH1A1 246/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | TSHR 689/4885GAA 422/4885ALDH1A1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.